UK Markets close in 3 hrs 34 mins
  • FTSE 100

    6,332.43
    -30.50 (-0.48%)
     
  • FTSE 250

    19,221.73
    -174.61 (-0.90%)
     
  • AIM

    1,038.72
    +0.69 (+0.07%)
     
  • GBP/EUR

    1.1178
    -0.0033 (-0.29%)
     
  • GBP/USD

    1.3328
    -0.0028 (-0.2119%)
     
  • BTC-GBP

    12,806.04
    -49.02 (-0.38%)
     
  • CMC Crypto 200

    333.66
    -36.86 (-9.95%)
     
  • S&P 500

    3,629.65
    -5.76 (-0.16%)
     
  • DOW

    29,872.47
    -173.77 (-0.58%)
     
  • CRUDE OIL

    45.37
    -0.34 (-0.74%)
     
  • GOLD FUTURES

    1,810.50
    -0.70 (-0.04%)
     
  • NIKKEI 225

    26,644.71
    +107.40 (+0.40%)
     
  • HANG SENG

    26,894.68
    +75.23 (+0.28%)
     
  • DAX

    13,315.83
    +29.26 (+0.22%)
     
  • CAC 40

    5,595.26
    +28.47 (+0.51%)
     

COMPASS Pathways plc to announce third quarter 2020 financial results on 12 November 2020

Compass Pathways
·2-min read

London, UK, Nov. 05, 2020 (GLOBE NEWSWIRE) --

COMPASS Pathways plc to announce third quarter 2020 financial results
on 12 November 2020

London, UK - 5 November 2020


COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the third quarter ended 30 September 2020, and provide an update on recent business developments, on 12 November 2020.

The management team will host a conference call at 1.00pm GMT (8.00am ET) on 12 November. The call can be accessed by dialling (833) 665-0659 from the United States, +1 (914) 987-7313 internationally, and 0800 028 8438 from the UK, followed by the conference ID: 9377988.

The call will also be webcast live on the Investors section of the COMPASS Pathways website. The webcast will be archived for 30 days.

-Ends-

About COMPASS Pathways

COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we are currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 20 sites across Europe and North America. We are headquartered in London, UK, with offices in New York, USA. Our vision is a world of mental wellbeing. www.compasspathways.com

Contacts:

COMPASS Pathways
Tracy Cheung, tracy@compasspathways.com, +44 7966 309024
Amy Lawrence, amy@compasspathways.com, +44 7813 777919

Westwicke (for investor enquiries)
Stephanie Carrington, stephanie.carrington@westwicke.com, +1 646-277-1282